Skip to main content
. 2022 Mar 15:eabn9243. doi: 10.1126/scitranslmed.abn9243

Fig. 1. Vaccine-induced antibody binding to the Spike protein of SARS-CoV-2 is maintained across variants of concern.

Fig. 1.

Individuals received the full dose regimen of the BNT162b2 mRNA vaccine (n = 11), mRNA-1273 vaccine (n=14), or the aluminum-adjuvanted inactivated particle vaccine CoronaVac (n=13). Samples were obtained from vaccine recipients 13 to 19 days after the second dose. IgM, IgA1, and IgG1 binding titers to D614G, Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529) VOC (A) RBDs or (B) full-length Spike protein were measured by a Luminex assay. The average value of technical replicates is shown. The data was corrected for background and negative values were set to 100 for graphing purposes. A two-sided Kruskal-Wallis test with a Benjamini-Hochberg post-test correcting for multiple comparisons was used to test for statistical differences between D614G and Omicron titers. P-values for significantly different features (p≤0.05) are shown; fold-change reduction of omicron titers compared to D614G are shown below each dataset. MFI, median fluorescence intensity.